76 related articles for article (PubMed ID: 16292537)
1. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL
Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537
[TBL] [Abstract][Full Text] [Related]
2. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
Congdon LM; Pourpak A; Escalante AM; Dorr RT; Landowski TH
Biochem Pharmacol; 2008 Feb; 75(4):883-90. PubMed ID: 18062937
[TBL] [Abstract][Full Text] [Related]
3. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
4. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
van Dijk AD; Hoff FW; Qiu Y; Hubner SE; Go RL; Ruvolo VR; Leonti AR; Gerbing RB; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; de Bont ESJM; Horton TM; Kornblau SM
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672531
[TBL] [Abstract][Full Text] [Related]
5. Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels.
Zafeiropoulou K; Kalampounias G; Alexis S; Androutsopoulou T; Katsoris P; Symeonidis A
Cureus; 2023 Dec; 15(12):e49843. PubMed ID: 38169896
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review.
Letafati A; Soheili R; Norouzi M; Soleimani P; Mozhgani SH
Med Oncol; 2023 Sep; 40(10):295. PubMed ID: 37689806
[TBL] [Abstract][Full Text] [Related]
7. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
Miyagawa N; Goto H; Ogawa A; Kikuta A; Kosaka Y; Sekimizu M; Tomizawa D; Toyoda H; Hiramatsu H; Hara J; Mochizuki S; Nakayama H; Yoshimura K; Iijima-Yamashita Y; Sanada M; Ogawa C
Int J Hematol; 2023 Aug; 118(2):267-276. PubMed ID: 37127801
[TBL] [Abstract][Full Text] [Related]
9. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.
Munir F; He J; Connors J; Garcia M; Gibson A; McCall D; Nunez C; Dinh CN; Robusto L; Roth M; Khazal S; Tewari P; Cuglievan B
Transl Pediatr; 2023 Mar; 12(3):487-502. PubMed ID: 37035397
[TBL] [Abstract][Full Text] [Related]
10. TRIM37 interacts with PTEN to promote the growth of human T-cell acute lymphocytic leukemia cells through regulating PI3K/AKT pathway.
Qu H; Gao-Wa H; Hou Y; Ren M; Li J; Jing B; Du Y
Front Oncol; 2022; 12():1016725. PubMed ID: 36923153
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
[TBL] [Abstract][Full Text] [Related]
12. Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.
Graiqevci-Uka V; Behluli E; Spahiu L; Liehr T; Temaj G
Curr Pediatr Rev; 2023; 19(2):150-156. PubMed ID: 36056858
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.
Lejman M; Kuśmierczuk K; Bednarz K; Ostapińska K; Zawitkowska J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575992
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia.
Jain H; Sengar M; Goli VB; Thorat J; Tembhare P; Shetty D; Bonda VNA; Nayak L; Subramanian PG; Bagal B; Patkar N; Sharma N; Gupta H; Gujral S
Blood Adv; 2021 Sep; 5(17):3436-3444. PubMed ID: 34461632
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.
Inaba H; Pui CH
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33946897
[TBL] [Abstract][Full Text] [Related]
16. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
17. Lack of Electron Acceptors Contributes to Redox Stress and Growth Arrest in Asparagine-Starved Sarcoma Cells.
Bauer C; Quante M; Breunis WB; Regina C; Schneider M; Andrieux G; Gorka O; Groß O; Boerries M; Kammerer B; Hettmer S
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499165
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.
Aplenc R; Meshinchi S; Sung L; Alonzo T; Choi J; Fisher B; Gerbing R; Hirsch B; Horton T; Kahwash S; Levine J; Loken M; Brodersen L; Pollard J; Raimondi S; Kolb EA; Gamis A
Haematologica; 2020 Jul; 105(7):1879-1886. PubMed ID: 32029509
[TBL] [Abstract][Full Text] [Related]
19. A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors.
Liu M; Tang X; Ding J; Liu M; Zhao B; Deng Y; Song Y
Pharm Res; 2019 Nov; 36(12):176. PubMed ID: 31686241
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
